Leiden, Netherlands and Mont-Saint-Guibert, Belgium (August 15, 2023) –
Ncardia and Cellistic are pleased to announce the appointment of Charles Jacques as Chief Financial Officer leading the global finance function for both organizations.
In his new role, Charles will leverage his experience in finance strategy for CDMO’s to help Ncardia and Cellistic accelerate their growth in the allogeneic immune cell therapy and drug discovery markets.
Charles joins Ncardia and Cellistic from strategy consulting firm Ekkofin, where he worked as director, specializing in fundraising and asset deals. Prior to this, Charles served in roles of increasing responsibility and finance leadership at MasTHerCell up to and after its acquisition by Catalent.
Gustavo Mahler, Ncardia and Cellistic CEO said: “Charles' experience in finance strategy for CDMO's will further enable us to grow and accelerate new applications that should transform the drug development and cell therapy landscape. I am very pleased with his addition to the Cellistic and Ncardia leadership team. ”
Charles Jacques, Ncardia and Cellistic CFO about his new role: “I am very excited to join Ncardia and Cellistic to participate in the development of new innovative treatments and improve patients’ quality of life. I like taking on challenges and I’m looking forward to doing so with the Ncardia and Cellistic teams.”
Launched in April 2022 as a subsidiary of Ncardia, Cellistic™ specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions the business to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia’s scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cells that deliver quality products at scale.
Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies in drug discovery to accelerate their development processes through the integration of human iPSC technologies. For more information, visit www.ncardia.com.
Cellistic Investor and Media Contact